Compounded Semaglutide FDA Update 2026: What Patients Need to Know

In early 2025, the FDA declared the shortage of branded semaglutide (Ozempic, Wegovy) resolved. This triggered changes in the compounding pharmacy landscape that affected millions of patients using more affordable alternatives. Understanding what actually changed — and what didn't — matters whether you're currently on compounded semaglutide or considering starting.

Background: How Compounding Under Shortage Rules Worked

Under Section 503A and 503B of the Food, Drug, and Cosmetic Act, compounding pharmacies can prepare drugs that are commercially unavailable or in shortage. When Ozempic and Wegovy faced severe supply constraints in 2022–2024, the FDA added semaglutide to the drug shortage list.

This created legal grounds for both: - 503A pharmacies (traditional compounding for individual patients) to prepare semaglutide per prescription - 503B outsourcing facilities (registered FDA-inspected facilities, compounding in bulk) to prepare semaglutide for distribution to prescribers

The shortage drove an entire industry: hundreds of telehealth companies, including early Marrow-style platforms, built GLP-1 services around compounded semaglutide at a fraction of branded costs.

What Changed When the FDA Resolved the Shortage

When FDA declared the shortage resolved, it issued guidance that: 1. 503A pharmacies must stop compounding copies of commercially available drugs — including semaglutide, now that Ozempic/Wegovy are in supply 2. 503B outsourcing facilities have a transition window, but ultimately face similar restrictions on compounding drugs that are commercially available without shortage

The practical effect: the large-scale compounded semaglutide market faces pressure. Some platforms have pivoted to tirzepatide (still differently positioned) or to niche compounded formulations with added B12, BPC-157, or modified delivery forms that may still have regulatory footing.

What Hasn't Changed

Several important things haven't changed:

The branded drugs remain expensive and coverage-limited. Resolving the shortage means Ozempic and Wegovy are on shelves — it doesn't mean insurance covers them. Most commercial insurance still does not cover GLP-1 medications for weight loss (only for diabetes), and the brand-name list price of $900–1,100/month is inaccessible for most patients.

Physician judgment still matters. FDA guidance on compounding is not a criminal prohibition — it's a regulatory framework with enforcement discretion. Physicians who determine a patient cannot use branded formulations (allergy to inactive ingredients, documented insurance denial, specific clinical need for a modified dose) have grounds for compounded prescriptions under personalized patient care arguments.

503B facilities still operate. The nation's licensed 503B outsourcing pharmacies have not shut down semaglutide production. They continue to supply telehealth platforms working within compliance frameworks. The regulatory pressure creates risk of enforcement, but licensed facilities operating with legal counsel continue to supply the market.

Tirzepatide compounding remains differently situated. Tirzepatide (branded Mounjaro/Zepbound) had separate shortage determinations and the regulatory picture is evolving on its own timeline.

What This Means for Marrow Patients

Marrow's pharmacy partnerships are with licensed 503B outsourcing facilities that operate within the current regulatory framework. Our medical team monitors the regulatory environment actively and will communicate directly with patients if availability changes.

The most important patient protection: working through a licensed telehealth provider, not a gray-market vendor. The FDA's enforcement concerns focus on unregulated online pharmacies shipping unlabeled peptides — not licensed medical practices working with inspected facilities.

Patients who contact us about supply concerns receive current, accurate information from our medical team. We do not make promises about indefinite compounded availability — because that would be irresponsible in a changing regulatory environment.

The Broader Picture

The GLP-1 shortage resolution represents the FDA catching up to a market that grew faster than the regulatory infrastructure. The branded manufacturers (Novo Nordisk, Eli Lilly) have advocated aggressively for enforcement against compounders — the market they created through their own supply failures.

The ultimate resolution likely involves: - Continued branded GLP-1 price pressure (both companies facing negotiation from CMS under drug pricing reform) - Insurance coverage expansion (several states have mandated coverage; federal movement is possible) - Regulatory clarity on what modified compounded formulations are legally distinct from branded drugs

The $900/month access gap that drove compounding demand hasn't been solved by resolving the shortage. Until it is, the market will find ways to serve patients who can't access branded medications.

What Patients Should Do

1. Know your source. If you're using compounded semaglutide, verify your pharmacy is a licensed 503B facility or has clear regulatory footing.

1. Have a backup plan. Ask your physician about tirzepatide as an alternative, which is clinically superior for most weight loss patients anyway.

1. Talk to your insurer. With documented obesity-related comorbidities, some insurance plans do cover Wegovy or Zepbound. A prior authorization attempt is worth making.

1. Don't buy from unvetted online sources. The enforcement risk and quality risk in gray-market channels are real. Stick with licensed telehealth platforms with transparent pharmacy partnerships.

Marrow will continue to provide GLP-1 access for qualified patients within the applicable regulatory framework. Our position is to keep patients on effective therapy — and to be transparent when that landscape changes.